SCHEMBL16007994

SCHEMBL16007994

Cc1[nH]c(-c2ccccc2Oc2ccccc2)c2cc(-c3nc(-c4ccccc4)no3)[nH]c(=O)c12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 14/20 0.57
NPC1 O15118 3/20 0.39
TP53 P04637 3/20 0.39
RAB9A P51151 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
NFKB1 P19838 2/20 0.39
NFKB2 Q00653 2/20 0.39
RELA Q04206 2/20 0.39
ALDH1A1 P00352 4/20 0.39
HSD17B10 Q99714 3/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HPGD P15428 2/20 0.38
PKM P14618 1/20 0.38
PTPN7 P35236 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16007884 0.95 BRD4 (0.54) BRD4NPC1TP53RAB9ASMN1; SMN2
SCHEMBL16007955 0.92 BRD4 (0.52) BRD4NPC1TP53RAB9AALDH1A1
SCHEMBL16007849 0.92 BRD4 (0.54) BRD4NPC1TP53RAB9ASMN1; SMN2
SCHEMBL16008288 0.91 BRD4 (0.59) BRD4KMT2AELANE
SCHEMBL16007867 0.89 BRD4 (0.53) BRD4NPC1TP53RAB9ASMN1; SMN2
SCHEMBL16008140 0.86 BRD4 (0.53) BRD4NPC1TP53RAB9ASMN1; SMN2
SCHEMBL16007937 0.86 BRD4 (0.54) BRD4NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL16008055 0.86 BRD4 (0.54) BRD4ELANE
SCHEMBL16008184 0.81 BRD4 (0.53) BRD4NPC1RAB9ASMN1; SMN2TDP1
SCHEMBL16007912 0.80 BRD4 (0.48) BRD4ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9050346-B2 Bromodomain inhibitors ABBVIE INC. (US) 2015-06-09 US claimed
US-20140256705-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2014-09-11 US claimed
EP-2970262-A1 BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2016-01-20 EP disclosed
US-9050346-B2 Bromodomain inhibitors ABBVIE INC. (US) 2015-06-09 US disclosed
WO-2014164771-A1 BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2014-10-09 WO disclosed
US-20140256705-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2014-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256705-A1 BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 BRD4 1/4885NPC1 2179/4885TP53 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.